

28 March 2022

Use of Biologic Medicines in Dermatology

Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

- Adalimumab – Humira 46
- Adalimumab Biosimilar 160
- Apremilast : Data unavailable as prescribed in the community
- Bimekizumab 0
- Brodalumab 0
- Certolizumab <5
- Dimethyl fumarate Data unavailable as prescribed in the community
- Etanercept – Enbrel 0
- Etanercept Biosimilar 9
- Guselkumab 86
- Infliximab – Remicade <5
- Infliximab Biosimilar 12
- Ixekizumab 45
- Risankizumab 51
- Secukinumab 42
- Tildrakizumab 7
- Ustekinumab 83

Q2. Could you please provide the numbers of patients treated for Hidradenitis-suppurativa ONLY in the last 3 months with the following biologic drugs:

- Adalimumab – Humira 18
- Adalimumab Biosimilar 11
- Infliximab – Remicade 0
- Infliximab Biosimilar 8
- Any other biologic drug (please name) <5 (STELARA)